Transcription-based prediction of response to IFNβ using supervised computational methods

PLoS Biology

Volumn 3, Issue 1, 2005, Pages

  Baranzini, Sergio E ^a   Mousavi, Parvin ^b   Rio, Jordi ^c   Caillier, Stacy J ^a   Stillman, Althea ^a   Villoslada, Pablo ^d   Wyatt, Matthew M ^a   Comabella, Manuel ^c   Greller, Larry D ^e   Somogyi, Roland ^e   Montalban, Xavier ^c   Oksenberg, Jorge R ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b QUEEN S UNIVERSITY   (Canada)

^c HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^d UNIVERSITY CLINIC OF NAVARRA   (Spain)

^e Biosystemix   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; RECOMBINANT BETA INTERFERON; RECOMBINANT PROTEIN;

ACCURACY; ADULT; AGED; ARTICLE; CONTROLLED STUDY; DATA ANALYSIS; DNA FOOTPRINTING; DRUG EFFECT; GENE EXPRESSION; GENETIC TRANSCRIPTION; HUMAN; MATHEMATICAL MODEL; MULTIPLE SCLEROSIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PREDICTION; RANDOMIZATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STATISTICAL ANALYSIS; ADOLESCENT; ALGORITHM; BIOLOGY; COMPUTER PROGRAM; DNA MICROARRAY; FEMALE; GENE EXPRESSION REGULATION; KINETICS; MALE; METABOLISM; METHODOLOGY; MIDDLE AGED; MONONUCLEAR CELL; TIME;

ADOLESCENT; ADULT; ALGORITHMS; COMPUTATIONAL BIOLOGY; FEMALE; GENE EXPRESSION REGULATION; HUMANS; INTERFERON-BETA; KINETICS; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; RECOMBINANT PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SOFTWARE; TIME FACTORS; TRANSCRIPTION, GENETIC;

EID: 20044373640     PISSN: 15449173     EISSN: None     Source Type: Journal    
DOI: 10.1371/journal.pbio.0030002     Document Type: Article

References (30)

1. Samuel CE, Knutson GS (1983) Mechanism of interferon action: Human leukocyte and immune interferons regulate the expression of different genes and induce different antiviral states in human amnion U cells. Virology 130: 474-484.
2. Tompkins WA (1999) Immunomodulation and therapeutic effects of the oral use of interferon-alpha: Mechanism of action. J Interferon Cytokine Res 19: 817-828.
3. Zhang X, Xu HT, Zhang CY, Liu JJ, Liu CM, et al. (1991) Immunomodulation of human cytomegalovirus infection on interferon system in patients with systemic lupus erythematosus. J Tongji Med Univ 11: 126-128.
4. Jacobs L, Salazar AM, Herndon R, Reese PA, Freeman A, et al. (1986) Multicentre double-blind study of effect of intrathecally administered natural human fibroblast interferon on exacerbations of multiple sclerosis. Lancet 2: 1411-1413.
5. Arnason BG (1996) Interferon beta in multiple sclerosis. Clin Immunol Immunopathol 81: 1-11.
6. Rio J, Nos C, Tintore M, Borras C, Galan I, et al. (2002) Assessment of different treatment failure criteria in a cohort of relapsing-remitting multiple sclerosis patients treated with interferon beta: Implications for clinical trials. Ann Neurol 52: 400-406.
7. Wiendl H, Hohlfeld R (2002) Therapeutic approaches in multiple sclerosis: Lessons from failed and interrupted treatment trials. BioDrugs 16: 183-200.
8. Mohr DC, Likosky W, Boudewyn AC, Marietta P, Dwyer P, et al. (1998) Side effect profile and adherence to in the treatment of multiple sclerosis with interferon beta-1a. Mult Scler 4: 487-489.
9. Olshen AB, Jain AN (2002) Deriving quantitative conclusions from microarray expression data. Bioinformatics 18: 961-970.
10. Hastie T, Tibshirani R, Friedman JH (2001) The elements of statistical learning: Data mining, inference, and prediction. New York: Springer. 533p.
11. Bertolotto A, Gilli F, Sala A, Audano L, Castello A, et al. (2001) Evaluation of bioavailability of three types of IFNbeta in multiple sclerosis patients by a new quantitative-competitive-PCR method for MxA quantification. J Immunol Methods 256: 141-152.
12. Wen X, Fuhrman S, Michaels GS, Carr DB, Smith S, et al. (1998) Large-scale temporal gene expression mapping of central nervous system development. Proc Natl Acad Sci U S A 95: 334-339.
13. D'Haeseleer P, Liang S, Somogyi R (2000) Genetic network inference: From co-expression clustering to reverse engineering. Bioinformatics 16: 707-726.
14. Efron B, Tibshirani R (1993) An introduction to the bootstrap. Boca Raton (Florida): Chapman and Hall. 436 p.
15. Chawla-Sarkar M, Lindner DJ, Liu YF, Williams BR, Sen GC, et al. (2003) Apoptosis and interferons: Role of interferon-stimulated genes as mediators of apoptosis. Apoptosis 8: 237-249.
16. Gniadek P, Aktas O, Wandinger KP, Bellmann-Strobl J, Wengert O, et al. (2003) Systemic IFN-beta treatment induces apoptosis of peripheral immune cells in MS patients. J Neuroimmunol 137: 187-196.
17. Sturzebecher S, Wandinger KP, Rosenwald A, Sathyamoorthy M, Tzou A, et al. (2003) Expression profiling identifies responder and nonresponder phenotypes to interferon-beta in multiple sclerosis. Brain 126: 1419-1429.
18. Weinstock-Guttman B, Badgett D, Patrick K, Hartrich L, Santos R, et al. (2003) Genomic effects of IFN-beta in multiple sclerosis patients. J Immunol 171: 2694-2702.
19. Lehner M, Felzmann T, Clodi K, Holter W (2001) Type I interferons in combination with bacterial stimuli induce apoptosis of monocyte-derived dendritic cells. Blood 98: 736-742.
20. Van Weyenbergh J, Wietzerbin J, Rouillard D, Barral-Netto M, Liblau R (2001) Treatment of multiple sclerosis patients with interferon-beta primes monocyte-derived macrophages for apoptotic cell death. J Leukoc Biol 70: 745-748.
21. Kayagaki N, Yamaguchi N, Nakayama M, Eto H, Okumura K, et al. (1999) Type I interferons (IFNs) regulate tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) expression on human T cells: A novel mechanism for the antitumor effects of type I IFNs. J Exp Med 189: 1451-1460.
22. Akbar AN, Lord JM, Salmon M (2000) IFN-alpha and IFN-beta: A link between immune memory and chronic inflammation. Immunol Today 21: 337-342.
23. Rengarajan J, Mowen KA, McBride KD, Smith ED, Singh H, et al. (2002) Interferon regulatory factor 4 (IRF4) interacts with NFATc2 to modulate interleukin 4 gene expression. J Exp Med 195: 1003-1012.
24. Grumont RJ, Gerondakis S (2000) Rel induces interferon regulatory factor 4 (IRF-4) expression in lymphocytes: Modulation of interferonregulated gene expression by rel/nuclear factor kappaB. J Exp Med 191: 1281-1292.
25. Roers A, Hochkeppel HK, Horisberger MA, Hovanessian A, Haller O (1994) MxA gene expression after live virus vaccination: A sensitive marker for endogenous type I interferon. J Infect Dis 169: 807-813.
26. DuPont SA, Goelz S, Goyal J, Green M (2002) Mechanisms for regulation of cellular responsiveness to human IFN-beta1a. J Interferon Cytokine Res 22: 491-501.
27. Sriram U, Barcellos LF, Villoslada P, Rio J, Baranzini SE, et al. (2003) Pharmacogenomic analysis of interferon receptor polymorphisms in multiple sclerosis. Genes Immun 4: 147-152.
28. Baranzini SE, Elfstrom C, Chang SY, Butunoi C, Murray R, et al. (2000) Transcriptional analysis of multiple sclerosis brain lesions reveals a complex pattern of cytokine expression. J Immunol 165: 6576-6582.
29. Thellin O, Zorzi W, Lakaye B, De Borman B, Coumans B, et al. (1999) Housekeeping genes as internal standards: Use and limits. J Biotechnol 75: 291-295.
30. Schmittgen TD, Zakrajsek BA (2000) Effect of experimental treatment on housekeeping gene expression: Validation by real-time, quantitative RTPCR. J Biochem Biophys Methods 46: 69-81.